{"drugs":["Azficel-T","Laviv"],"mono":{"0":{"id":"929962-s-0","title":"Generic Names","mono":"Azficel-T"},"1":{"id":"929962-s-1","title":"Dosing and Indications","sub":{"0":{"id":"929962-s-1-4","title":"Adult Dosing","mono":"<b>Cosmetic surgery of nasolabial fold:<\/b> 0.1 mL\/linear centimeter into the nasolabial fold wrinkles; 3 treatment sessions (up to 2 mL (2 vials) of azficel-T per session) at 3 to 6 week intervals "},"1":{"id":"929962-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in infants and children "},"3":{"id":"929962-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Cosmetic surgery of nasolabial fold<br\/>"}}},"3":{"id":"929962-s-3","title":"Contraindications\/Warnings","sub":[{"id":"929962-s-3-9","title":"Contraindications","mono":"<ul><li>allogeneic use; serious immunological reactions can occur if the skin used to produce azficel-T was not from the treating patient<\/li><li>hypersensitivity to azficel-T or any component of the product<\/li><li>hypersensitivity to gentamicin, amphotericin, dimethyl sulfoxide (DMSO) or material of bovine origin<\/li><li>infection (active) of the face area<\/li><\/ul>"},{"id":"929962-s-3-10","title":"Precautions","mono":"<ul><li>autoimmune disease (active), immunosuppressed patients, or patients requiring immunosuppressant therapy; risk of infection<\/li><li>coagulopathy disorder; increased risk for severe injection-site bleeding or bruising<\/li><li>concomitant use of aspirin, NSAIDs, or anticoagulants; increased risk for severe injection-site bleeding or bruising; use not recommended<\/li><li>concomitant use with ongoing chemotherapeutic drug therapy; use not recommended<\/li><li>genetic disorders affecting the skin, including Ehlers-Danlos syndrome, achondroplasia, epidermolysis bullosa, osteogenesis imperfecta, Marfan syndrome, or ataxia-telangiectasia; use not recommended<\/li><li>health care professionals; adventitious viruses in treated patients not routinely tested; use proper universal precautions when handling the product or biopsy material<\/li><li>herpes labialis has been reported<\/li><li>hypersensitivity reactions have occurred<\/li><li>keloid or hypertrophic scarring, history of; use not recommended<\/li><li>skin cancer, history of; use not recommended<\/li><li>sterility test results of product in full may not be available prior to azficel-T administration; microbial contamination may be reported after injection<\/li><li>vasculitis (leukocytoclastic) has been reported<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"929962-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"929962-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"929962-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Erythema at injection site (16%), Injection site bruising (11%), Injection site pain (6%), Swelling at injection site (14%)<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Hypersensitivity angiitis (less than 1%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><\/ul>"},"6":{"id":"929962-s-6","title":"Drug Name Info","sub":{"0":{"id":"929962-s-6-17","title":"US Trade Names","mono":"Laviv<br\/>"},"3":{"id":"929962-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"929962-s-7","title":"Mechanism Of Action","mono":"The mechanism of action of azficel-T is unknown.<br\/>"},"9":{"id":"929962-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>for intradermal use only<\/li><li>do not dilute<\/li><\/ul><\/li><li><b>Intradermal<\/b><br\/><ul><li>following receipt of azficel-T (11 to 22 weeks after manufacturer receives patient's biopsy samples), confirm unique patient identifier on the azficel-T vial matches identity of patient receiving treatment<\/li><li>allow vial to reach room temperature; examine for evidence of damage or contamination<\/li><li>gently invert vial and tap the top to release any trapped fluid; each vial contains sufficient product to administer 1 mL<\/li><li>prepare a minimum of 4 sterile small unit (eg, 0.5 mL) syringes and detachable large bore (eg, 21-gauge) needles; unscrew the vial and withdraw up to 0.5 mL into each syringe<\/li><li>replace 21-gauge needle with a short (eg, 1\/2 inch) 30 gauge needle prior to administration<\/li><li>injection areas should be free of cosmetics, hair, or facial jewelry; remove any topical anesthetic (if used) from the face; do not use injectable local anesthetics; clean the injection area with aseptic solution and make sure patient is in comfortable (eg, recumbent) position<\/li><li>inject into superficial papillary dermis along the line of each nasolabial fold; needle should be visible through epidermis; blanching and a fluid bleb should be present at injection site; apply multiple injections (0.1 mL\/linear centimeter) and overlap injection areas slightly; ensure end of needle is inserted slightly adjacent to previous injection site<\/li><li>leave injection area undisturbed; do not rub, massage, or compress; apply cold pack (do not place ice directly on skin) for 2 to 3 minutes<\/li><\/ul><\/li><\/ul>"},"10":{"id":"929962-s-10","title":"Monitoring","mono":"improvement in appearance of moderate to severe nasolabial fold wrinkles is indicative of efficacy<br\/>"},"13":{"id":"929962-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause injection-site redness, bruising, swelling, pain, hemorrhage, edema, nodules, papules, irritation, dermatitis, and pruritus.<\/li><li>Advise patient to immediately report signs\/symptoms of infection (fever over 100 degrees F; redness, warmth, or pain at injection or biopsy sites persisting over 3 days).<\/li><li>Advise patient to immediately report signs\/symptoms of allergic reaction (difficulty breathing; trouble swallowing; rash; hives; severe redness and swelling).<\/li><li>Following treatment, do not apply ice to the face, do not wash the site of injections for at least 24 hours, and do not scrub, rub or manipulate the treatment area for at least 72 hours.<\/li><li>Following treatment, do not apply topical products (eg, sunscreen, make-up, facial creams) to the treatment area for 72 hours.<\/li><li>Instruct patient to avoid aspirin and NSAIDs due to increased risk of bleeding and bruising at biopsy and\/or injection sites.<\/li><\/ul>"}}}